CD274 and cancer: One of them was Keynote-024, a randomized Phase III study comparing the benefits of first line therapy with pembrolizumab to platinum-based chemotherapy in patients with advanced NSCLC expressing PD-L1 on the surface of at least 50% of cancer cells.